Frontlight ResearchEarly access
Not yet taking people in BelgiumPhase 3
Tests daily oxytocin nasal spray for stress and repetitive behaviors in adults with autism
Tests a daily nasal spray against a dummy spray in adults with autism.
Key facts
- Who runs it
- UZ Leuven
- Where
- Geel, Jette, Leuven, and Mons, BelgiumSee the 4 sites
- Trial code
- Registry title
- Assessment of self-perceived stress and repetitive behaviors after six weeks of daily intranasal oxytocin administration versus placebo: a randomised, multicentre, parallel group pragmatic trial in 210 men and women with autism
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 210 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 30 Jun 2030
- Type of study
- Interventional
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with autism who say they have felt a lot of stress for at least the past month. It compares oxytocin nasal spray with placebo for six weeks.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Diagnosis of autism spectrum disorder (or autistic disorder, Asperger syndrome or PDD-NOS), made by a multidisciplinary team. Mild intellectual disability is allowed if the person is not under legal guardianship and reads at about 4th-grade level.
- Earlier treatment
- No long-term oxytocin treatment in the last 10 years.
Main reasons for not taking part
- Taking anti-epileptic medication, or having a serious unstable medical condition
- Severe intellectual disability
- Known syndrome affecting reproductive hormones, such as Prader-Willi or Angelman syndrome
- Pregnant, breast-feeding, or planning pregnancy during the spray period
- Gender-affirming hormones or long-term high-dose sex hormones
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Participants eligible for inclusion in this Trial must meet all of the following criteria: 1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures 2. Must be at least 18 years of age at the time of signing the Informed Consent Form (ICF) 3. Diagnosis of Autism Spectrum Disorder (ASD) according to DSM-5 criteria OR Autistic Disorder (AD), Asperger Syndrome (AS) or Pervasive Developmental Disorder – Not Otherwise Specified (PDD-NOS) according to DSM-IV criteria, as established by a multidisciplinary team; 4. Participants are eligible if they self-report experiencing heightened stress for at least the past month. A formal questionnaire or cut-off score is not applied, allowing inclusion to be based on self-reported need and clinical judgment. All participants that are considered for Trial participation, per the above criteria will be documented via applicable log forms in Investigator Site File (including Screen Failures)
Who cannot take part
- Participant actively takes anti-epileptic medication or has a clinically significant and unstable medical condition. Conditions include hematological (e.g., severe anemia, clinically significant thrombocytopenia), endocrine (e.g., uncontrolled hypo-/hyperthyroidism, uncontrolled diabetes), cardiovascular (including any rhythm disorder; e.g., atrial fibrillation/flutter, supraventricular tachycardia, heart failure, uncontrolled hypertension), respiratory (e.g., moderate-to-severe COPD, severe or poorly controlled asthma), renal (e.g., moderate-to-severe chronic kidney disease, dialysis), hepatic (e.g., cirrhosis, active hepatitis), or gastrointestinal disease (e.g., malabsorption syndromes, major gastrointestinal surgery such as gastric bypass), ongoing oncological disorders, that may influence the metabolism of oxytocin (IMP). 2. Individuals with a severe intellectual disability are excluded from participation due to concerns regarding their capacity to provide independent informed consent, understand study procedures, self-administer the nasal spray, and complete self-report questionnaires. Individuals with a mild intellectual disability may be included, provided they are not under legal guardianship and demonstrate a literacy level at or above the equivalent of fourth grade in primary education. In the Belgian context, this corresponds to minimally having completed the 4th grade level in Special Education Primary School of type 9 or type 8 education in Flanders, or in type 8 education in Wallonia. 3. Participant has a known syndrome that interacts with the reproductive hormonal system (e.g. Prader-Willi or Angelman syndrome); 4. Participant who has had previous chronic treatment with oxytocin in the last 10 years; 5. Known hypersensitivity to active substance or ingredients in the nasal sprays, including e.g. (history of) latex allergy; 6. Use of any of the following medicinal products during the nasal spray administration period: - prostaglandins or their analogues - inhalation anesthetics - systemic vasoconstrictors or sympathomimetic agents - caudal anesthesia 7. Current participation in another interventional Trial with an investigational medicinal product (IMP) or device; 8. Individuals of childbearing potential will be excluded if they are pregnant (as determined by a urine pregnancy test at baseline [T0] prior to randomization), are breast-feeding, or intend to become pregnant during the nasal spray administration period. To minimize the risk of pregnancy, individuals of childbearing potential are required to use effective contraception or to abstain from vaginal intercourse for the duration of the nasal spray administration period. 9. Exposure to gender-affirming hormonal regimens or other high-dose or long-term exogenous sex hormone administrations (e.g., for gynecological disorders) resulting in substantial, sustained changes of endogenous sex hormone profiles constitutes an exclusion criterion, given current uncertainties regarding interactions with intranasal oxytocin and the potential impact on safety assessment and interpretability of study outcomes. Use of standard-dose oral contraceptives does not constitute an exclusion
Where in Belgium
- OPZ GeelGeel, BelgiumNot yet recruiting
- UZ BrusselJette, BelgiumNot yet recruiting
- UZ LeuvenLeuven, BelgiumNot yet recruiting
- SUSA MonsMons, BelgiumNot yet recruiting
About the trial
What the trial wants to find out
Change from baseline after oxytocin administration on self-perceived stress
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Assessment of self-perceived stress and repetitive behaviors after six weeks of daily intranasal oxytocin administration versus placebo: a randomised, multicentre, parallel group pragmatic trial in 210 men and women with autism
- Plain-language title
- Tests daily oxytocin nasal spray for stress and repetitive behaviors in adults with autismGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 3 November 2026